Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0952W HIGH $2.60
Volume
102.79 K
Value Traded
979.56 K
Short % Float
10.74%
Days to Cover
7.0
-6.49%Week
-28%1 Month
-16.76%3 Month
-2.04%6 Month
-88.79%5 Year
-82.82%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
39.97 M
EPS (TTM)
-0.66
P/E Ratio
-
Ent. Value
21.83 M
Total Shares
27.75 M
Float Shares
24.75 M
Insiders
10.81%
Institutions
15.95%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
INMB Catalyst Timeline
Dated clinical, regulatory and corporate events for INmune Bio Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for INmune Bio Inc.
637Total events
33Upcoming
94Tier-1 (high impact)
2017 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseEbstrocel™Corporate
INmune Bio enters Master Services Agreement with Uniphar for Ebstrocel commercialization
Recessive Dystrophic Epidermolysis Bullosasource ↗
●Other Regulator MilestoneEbstrocel™Ex-US Regulatory
Final pre-MAA package submitted to MHRA for Ebstrocel in RDEB
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
▲Partnership / LicenseXProCorporate
INmune Bio and Quantum Computing Inc. announce collaboration to apply quantum computing and AI to XPro research
Alzheimer's disease and other disease conditionssource ↗
●Management ChangeCorporate
Appointment of R. Duane Clark II and James Sapirstein to Board of Directors
●EU Orphan DesignationEbstrocel™Ex-US Regulatory
EMA Orphan Drug Designation application submitted for Ebstrocel in RDEB
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
●Other Regulator MilestoneEbstrocel™Ex-US Regulatory
Pre-MAA Scientific Advice package submitted to EMA for Ebstrocel
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
●Type B MeetingEbstrocel™FDA Meeting
Pre-MAA Scientific Advice package submitted to EMA for Ebstrocel
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
●Partnership / LicenseCorporate
Named founding member of American Biotech Innovation Alliance
▲Oral PresentationXPro1595Presentation
Expanded Phase 2 imaging analyses presented at AAIC
Alzheimer's diseasesource ↗
▲Other Regulator MilestoneEx-US Regulatory
Received A$4.2 million R&D tax rebate from Australia
▲Other Regulator MilestoneEx-US Regulatory
Received approximately $4.2 million R&D cash rebate from Australia
▲Manufacturing MilestoneCORDStrom™FiledCMC / Inspection
First commercial-ready umbilical cord tissue processed at CGT Catapult
▲Manufacturing MilestoneEbstrocel™CMC / Inspection
First US tested master cell banks for Ebstrocel to be generated from commercial-ready process
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
▲Fast Track DesignationXPro1595Designation
FDA Fast Track designation granted for XPro1595
Alzheimer's diseasesource ↗
▲End Of Phase 2 MeetingXPro1595FDA Meeting
Successful End-of-Phase 2 meeting with FDA for XPro1595
Alzheimer's diseasesource ↗
▲FDA Feedback ReceivedEbstrocel™FDA Meeting
MHRA written guidance supporting planned Conditional Marketing Authorization application
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
▲PublicationXPro1595Presentation
Publication of preclinical study in Journal of Neurotrauma showing XPro1595 prevents brain-injury-induced Alzheimer's pathology, memory loss, and pain
traumatic brain injury, Alzheimer's diseasesource ↗
◆Poster PresentationXPro1595Presentation
Poster presentation of expanded imaging analysis from MINDFuL study at AAIC 2026
early Alzheimer's diseasesource ↗
●Timing GuidanceEbstrocel™Presentation
UK MAA submission to MHRA expected by end of Q3 or early Q4 2026
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
▲Manufacturing MilestoneEbstrocel™CMC / Inspection
First commercial-ready umbilical cord tissues processed at Cell and Gene Therapy Catapult
RDEBsource ↗
▲Other Regulator MilestoneEbstrocel™Ex-US Regulatory
MHRA written alignment received for UK MAA
RDEBsource ↗
▲Patent GrantedCORDStrom™FiledIP / Competition
CORDStrom platform patent application advanced to U.S. national phase
▲Partnership / LicenseCORDStrom™FiledCorporate
Expanded agreement with Anthony Nolan Cord Blood Bank
▲Primary Endpoint MetXPro1595Clinical Data
Statistically significant effect on white matter myelin MRI biomarker in Phase 2 MINDFuL trial
Alzheimer's diseasesource ↗
▲PublicationXPro1595Presentation
Journal of Neurotrauma study published on XPro1595 in TBI model
Traumatic brain injurysource ↗
▲Fast Track DesignationXPro1595Designation
FDA Fast Track designation for XPro1595 in early Alzheimer's disease
early Alzheimer's diseasesource ↗
▲MHRA MilestoneEbstrocel™Ex-US Regulatory
MHRA approved Pediatric Investigation Plan for Ebstrocel
Recessive Dystrophic Epidermolysis Bullosa (RDEB)source ↗
▲Full ResultsXPro1595Clinical Data
Statistically significant treatment effect on myelin in full mITT population (p=0.0028) and biomarker-enriched patients (p=0.0098)
early Alzheimer's diseasesource ↗
▲Topline ReadoutXPro1595Clinical Data
Positive topline imaging results reported for XPro in early Alzheimer's disease
early Alzheimer's diseasesource ↗
●EU MAA SubmissionCORDStrom™FiledEx-US Regulatory
MAA submission to MHRA planned for mid-summer 2026
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
▲Other Regulator MilestoneEx-US Regulatory
Received approximately $0.4 million R&D rebate from the United Kingdom
▲Full ResultsXProClinical Data
Phase 2 MINDFuL trial results published in NPJ Dementia
Alzheimer's disease with inflammationsource ↗
▲Fast Track DesignationXPro1595Designation
FDA granted Fast Track designation for XPro in early Alzheimer's disease
early Alzheimer's diseasesource ↗
▲MHRA MilestoneCORDStrom™FiledEx-US Regulatory
MHRA pre-MAA Scientific Advice meeting written alignment received
Recessive Dystrophic Epidermolysis Bullosa (RDEB)source ↗
▲MHRA MilestoneEbstrocel™Ex-US Regulatory
MHRA pediatric feedback recognizes MissionEB Phase 2 data as demonstrating clinically meaningful symptomatic benefit
Recessive Dystrophic Epidermolysis Bullosa (RDEB)source ↗
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results and Corporate Update Conference Call
◆Breakthrough Therapy DesignationCORDStrom™FiledDesignation
Submit for Breakthrough designation in US
RDEBsource ↗
◆MHRA MilestoneCORDStrom™FiledEx-US Regulatory
Face-to-face meeting with MHRA
recessive dystrophic epidermolysis bullosasource ↗
▲Oral PresentationINB03Presentation
AACR 2026 preclinical data presented for INB03
HER2-positive breast cancersource ↗
▲Partnership / LicenseCorporate
Expanded collaboration with Anthony Nolan for CORDStrom platform
◆Poster PresentationINB03Presentation
Poster presentation at AACR 2026: Soluble TNF blockade overcomes TKI resistance in HER2-positive breast cancer
HER2-positive breast cancersource ↗
◆MHRA MilestoneCORDStrom™FiledEx-US Regulatory
Full MAA filing with MHRA targeted for mid-summer 2026
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
◆Quarterly UpdateCorporate
Year End 2025 Financial Results and Corporate Update Conference Call
▲End Of Phase 2 MeetingXProFDA Meeting
Positive alignment with FDA at End-of-Phase 2 meeting
early Alzheimer's diseasesource ↗
▲Oral PresentationXProPresentation
Plenary presentation at AD/PD 2026 featuring MINDFuL trial results
early Alzheimer's diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How INMB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-12 | XPro (XPro1595) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 31%
Micro Cap(rank 204 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| XPro1595 Small moleculeCompletedNCT03943264 | Alzheimer Disease | Phase 2 | COMPLETED | 227 | Sep 1, 2021 | ||||||
| INKmune Monoclonal antibodyCompletedNCT06056791 | Cancer | Phase 1 | COMPLETED | 12 | Sep 10, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every INMB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| XPro Fast Track | early Alzheimer's disease | Phase 2 | 2026-07-09 | statistically significant treatment difference at Week 24 (p < 0.01)Read More | INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAICRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Juda ScottDirector | Option | 14,801 86,404 held | $1.40 | 07/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INMB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLCput | 0.1 % | 817.74 K | 354.00 K |
INMB Institutional Ownership Trends
INMB Short Interest
Shares sold short, counted twice a month.
10.74%
Short % of Float
of tradable shares sold short
2.7M
Shares Sold Short
+18.1% vs prior count
7.0 High
Days to Cover
trading days of normal volume to buy every short share back
381.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INMB ranks across every disease it competes in
Competitive Position is a premium feature
See how INMB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINMB News
INMBINmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
INmune Bio submitted its final pre-MAA package for Ebstrocel to the MHRA, targeting a full submission in February 2027. The company expects potential UK approval by mid-2027, accelerated by improved manufacturing progress. A U.S. BLA is also planned for Q2 2027, aiming for traditional or accelerated approval.
Read more →INMBINmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
INmune Bio has signed a Master Services Agreement with Uniphar to facilitate the commercialization of Ebstrocel™, an allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa. The initial focus will be on named-patient access in select European and MENA markets. This partnership aims to provide a capital-efficient path for broader distribution as regulatory approvals are secured.
Read more →INMBINmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™
INmune Bio Inc. has partnered with Quantum Computing Inc. to leverage quantum computing and AI for advancing Alzheimer's drug research with XPro. This collaboration aims to analyze extensive clinical data to uncover new treatment indications and biomarkers. It marks QCi's first commercial engagement in the pharmaceutical sector, showcasing the application of quantum optimization in drug development.
Read more →INMBINmune Bio to Attend the 2026 Maxim Growth Summit
INmune Bio Inc. will attend the 2026 Maxim Growth Summit from October 12-14 at The Hard Rock Hotel NYC. The company will engage with institutional investors and present on an Immunology & Inflammation Therapies Panel. Keynote speakers include industry leaders, and portions of the event will be streamed online.
Read more →INMBINmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
INmune Bio has appointed R. Duane Clark II and James Sapirstein to its Board of Directors to enhance its commercialization strategy for Ebstrocel. Clark's experience in rare diseases and Sapirstein's background in biopharmaceutical business development are expected to strengthen the company's market access and strategic partnerships. These appointments align with INmune Bio's goal of advancing its late-stage product platforms.
Read more →INMBINmune Bio to Present at the H.C. Wainwright Global Investment Conference
INmune Bio Inc. will present at the H.C. Wainwright Global Investment Conference from September 14-16, 2026. CEO David Moss will host one-on-one meetings and present on September 14 at 10:30 AM ET. The company is focused on treatments targeting the innate immune system and is advancing two late-stage product platforms towards regulatory milestones.
Read more →INMBINmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
INmune Bio has submitted an Orphan Drug Designation application and a Scientific Advice package to the EMA for Ebstrocel™, aimed at treating recessive dystrophic epidermolysis bullosa (RDEB). These filings support a planned Marketing Authorization Application (MAA) in the EU by Q1 2027. The company is also targeting a UK MAA in Q4 2026 and a U.S. BLA in Q1 2027, marking significant progress in their regulatory strategy.
Read more →INMB▲ +9.2%on this news
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress
INmune Bio Inc. reported its Q2 2026 financial results and highlighted significant advancements in its clinical programs. The company secured regulatory approvals for Ebstrocel™, positioning it for a UK MAA submission, while XPro™ received FDA Fast Track designation, enhancing its development for early Alzheimer's disease. Both platforms are on track for upcoming regulatory filings and trials.
Read more →INMBINmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
INmune Bio Inc. will report its second quarter 2026 financial results on August 6, 2026, during a conference call at 4:30 PM ET. The company is focused on developing treatments targeting the innate immune system, with two late-stage product platforms, CORDStrom and XPro1595, advancing toward regulatory submissions. XPro1595 has received FDA Fast Track designation, indicating promising development potential.
Read more →INMBINmune Bio Receives R&D Rebates of Approximately $4.6 Million
INmune Bio Inc. announced the receipt of approximately $4.6 million in R&D cash rebates from Australia and the UK. This funding enhances the company's financial stability and extends its cash runway as it progresses toward regulatory filings for its therapies. The rebates are part of government programs supporting R&D in these regions.
Read more →INMBINmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
INmune Bio has established a Scientific Advisory Board to support the late-stage development of Ebstrocel for recessive dystrophic epidermolysis bullosa and to guide the expansion of its CORDStrom platform. The board consists of experts in MSC biology and clinical translation, who will advise on regulatory strategies, trial designs, and additional indications. This initiative aims to enhance the scientific and clinical framework for Ebstrocel and explore new applications for CORDStrom.
Read more →INMBINmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
INmune Bio has achieved a significant milestone by completing commercial-ready manufacturing for its CORDStrom™ platform. This advancement supports the planned Phase 3 confirmation trial and regulatory submissions in the US, EU, and UK. The company is now equipped to generate master cell banks for Ebstrocel™, aimed at treating recessive dystrophic epidermolysis bullosa (RDEB). INmune Bio's efforts align with the MHRA's draft regulatory framework for rare disease therapies.
Read more →INMBINmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
INmune Bio's new peer-reviewed study demonstrates that XPro1595 can prevent Alzheimer's pathology and cognitive deficits induced by traumatic brain injury. The research identifies soluble TNF as a critical link between head injuries and Alzheimer's disease, showing that neutralizing this cytokine can mitigate the associated risks. The findings support the potential of XPro1595 in treating Alzheimer's and related conditions.
Read more →INMBINmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
INmune Bio Inc. announced positive Phase 2 imaging data for XPro in early Alzheimer's disease, showing significant treatment-related changes in white matter myelin integrity at Week 24. The data, to be presented at the AAIC, highlights the concordance of white matter and gray matter imaging endpoints, supporting the drug's biologic activity. The findings suggest that XPro may engage relevant biology earlier than traditional volumetric approaches.
Read more →INMBINmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
INmune Bio has advanced its CORDStrom™ platform patent application into the U.S. national phase, following a favorable opinion during the PCT application process. This move solidifies the company's intellectual property strategy and aims to protect its lead product, Ebstrocel, for epidermolysis bullosa. The patent, if granted, could provide exclusive commercial protection until at least 2045.
Read more →INMB▲ +10.4%on this news· ran to +21% by day 3
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
INmune Bio Inc. has received MHRA approval for the Pediatric Investigation Plan (PIP) for Ebstrocel™, aimed at treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). This approval is a crucial step towards the Marketing Authorization Application (MAA) submission in the UK, aligning with the company's timeline for regulatory filings. The swift approval reflects the strength of the clinical data and addresses significant unmet medical needs in a vulnerable patient population.
Read more →INMBINmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
INmune Bio has received positive feedback from the MHRA regarding its planned 2026 Marketing Authorization Application for CORDStrom™ in treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). The agency confirmed alignment on the clinical and manufacturing strategies, acknowledging the Phase 2 data as showing significant symptomatic benefits. However, the study's limitations regarding durable wound closure were noted, prompting refinements in the upcoming Phase 3 trial.
Read more →INMBINmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
INmune Bio reported significant results from its Phase 2 MINDFuL trial of XPro1595 in Alzheimer's patients, showing a strong treatment effect on white matter MRI biomarkers. The findings support the company's precision-medicine approach and align with FDA Fast Track designation for further development. The trial demonstrated enhanced efficacy in patients with elevated inflammatory markers, reinforcing the drug's potential in treating neuroinflammation.
Read more →INMB▼ -7.7%on this news
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
INmune Bio has published results from its Phase 2 MINDFuL trial in Alzheimer's disease, demonstrating the efficacy of XPro™ in patients with inflammation. The study showed positive trends across various cognitive and biomarker endpoints without any observed amyloid-related imaging abnormalities. The findings suggest a promising direction for future clinical trials, particularly in an enriched patient population.
Read more →INMB▲ +15.1%on this newsshared move
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
INmune Bio has received FDA Fast Track designation for XPro1595, a selective soluble TNF inhibitor, aimed at treating early Alzheimer's disease. This designation highlights the urgent need for innovative therapies that address neuroinflammation, a key factor in cognitive decline. The company anticipates closer collaboration with the FDA to expedite the development process.
Read more →About INmune Bio Inc.
Headquarters225 NE MIZNER BLVD, SUITE 640, BOCA RATON, FL, 33432
BIOPHARMAWATCH ELITE PLUS
Trade the next INMB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime